objeCtives: The purpose of this analysis was to quantify the cost-effectiveness of recombinant follitropin alfa (r-hFSH) and highly purified urinary follicle stimulating hormone (uFSH-HP) in the in-vitro fertilization (IVF) process. Methods: An Excel-based model estimated the drug cost per pregnancy and drug cost per live birth resulting from a hypothetical cohort of 1000 women undergoing IVF in Germany. Model inputs were taken from peer-reviewed published literature, and used to estimate the number of embryos generated per IU of gonadotropin used for ovarian stimulation. The cohort then underwent multiple rounds of embryo transfers (ETs) until embryo exhaustion or pregnancy as dictated by literature values. The obtained pregnancy rates were multiplied by the percentage of live births achieved per pregnancy according to the 2012 German IVF Registry to generate the live birth analysis. The cost inputs for r-hFSH and for uFSH-HP were ex-factory prices provided by Merck Serono affiliates in Germany. Cost inputs were limited to the cost of drug, as medical costs associated with the IVF procedure were assumed to be equal for both r-hFSH and uFSH-HP, and would not affect the comparison. All of the model outputs were age-agnostic and did not take into consideration procedural differences amongst fertility clinics, as the referenced clinical studies did not provide these details. Results: Treatment with r-hFSH resulted in a cost per pregnancy of 173€ (235USD, 10%) (Bergh et al.) and 47€ (64USD, 2%) (Frydman et al.) less than treatment with uFSH-HP. The cost per live birth was 622€ (846USD, 15%) (Bergh et al.) and 312€ (424USD, 6%) (Frydman et al.) less with r-hFSH than for uFSH-HP. ConClusions: r-hFSH minimises the cost per pregnancy and cost per live birth in Germany. The results of the model demonstrate that r-hFSH represents a cost-effective gonadotropin to use for IVF ovarian stimulation.
PIH43 A Cost-MInIMIzAtIon AnAlysIs of CArBetoCIn for tHe PreVentIon of PostPArtuM HeMorrHAGe In CAnAdA
Mills F. 1 , Siu E. 1 , Poinas A. C. 1 , Chamy C. 2 1 Wyatt Health Management, Oakville, ON, Canada, 2 Ferring Pharmaceuticals, Toronto, ON, Canada objeCtives: The objective of this analysis is to demonstrate the economic value of Duratocin ® in the prevention of postpartum hemorrhage from uterine atony during active management of the third stage of labour in elective caesarean section delivery. Methods: We analyzed the economic value of Duratocin ® (carbetocin) in relation to the comparators most commonly encountered in clinical practice, and recommended in the clinical practice guidelines of the Society of Obstetricians and Gynecologists of Canada. We modeled the treatment pathways as described in the guidelines, and also the use of uterotonics encountered in typical Canadian practice, i.e. as a second-line intervention. Assuming that the ultimate incidence of postpartum hemorrhage is equal between all treatment strategies, we constructed costminimization models in TreeAge Pro (2013), with a time horizon of 8 hours. Transition probabilities were derived from the literature, and costs and resource consumption data were obtained from hospital databases and input from health care professionals. Results: Duratocin ® was shown to be the lowest cost treatment strategy in the prevention of postpartum hemorrhage in elective caesarean section delivery using either guidelines or typical-use treatment pathways. The total expected cost of the carbetocin treatment strategy under the SOGC Guidelines scenario is $22.12, vs. $24.91 for the oxytocin strategy. In the typical use scenario the results are even clearer, with carbetocin providing very substantial cost-savings compared to ergonovine or carboprost. ConClusions: These results were robust to all sensitivity analyses in the case of the typical-use scenario. In the SOGC Guidelines scenario the results were robust to all sensitivity analyses except the dosing of ergonovine.
PIH44 A Cost MInIMIsAtIon AnAlysIs of GonAdotroPIns for In VItro fertIlIzAtIon oVArIAn stIMulAtIon on ooCyte-And eMBryo-BAsed endPoInts
Nanguneri S. 1 , Ezcurra D. 1 , Cespedes A. 1 , Xenakis A. 2 , Beckerman R. 2 1 EMD Serono, Rockland, MA, USA, 2 CBPartners, New York, NY, USA objeCtives: The purpose of this analysis was to quantify the cost-effectiveness of recombinant follitropin alfa (r-hFSH) and highly purified human menopausal gonadotropin (HP-hMG) in the in-vitro fertilization (IVF) process. Methods: An Excel-based model was constructed to estimate the cost per oocyte retrieved, cost per embryo generated, and cost per optimal chance of live birth for r-hFSH and HP-hMG in Sweden.
Calgary and Saskatchewan HTS protocols were found to be costly compared to LTS with the Calgary protocol being the most costly. The Saskatchewan protocol was found to be less costly than the Calgary protocol primarily due to employing ultrasound as the initial confirmatory diagnostic which reduces the number of Hysterosalpingogram (HSG) procedures conducted compared to the Calgary protocol. However, while HTS is more costly than LTS, it was also more effective. The costs saved per successful procedure lost by switching from LTS to the Saskatchewan protocol or the Calgary protocol was $3,588 and $4,789, respectively. This result suggests that the Saskatchewan protocol is cost effective compared to the Calgary protocol (i.e. within HTS comparison) because the Saskatchewan protocol saves more money for a unit of effectiveness lost. ConClusions: The existing evidence suggest that compared to LTS, HTS is more costly but also more effective. While replacing eligible LTS procedures with HTS will result in costs decision makers will need to determine whether the amount of costs outweighs the amount of effectiveness gains. Mbarara, Uganda, 3 Mbarara Regional Referral Hospital, Mbarara, Uganda objeCtives: Prenatal distribution of misoprostol has been advocated as a strategy to increase access to uterotonics during the third stage of labor to prevent Post Partum Hemorrhage (PPH). The objective of this study was to project the potential cost-effectiveness of this strategy in Uganda from both governmental (payer) and societal perspectives. Methods: To compare prenatal misoprostol distribution to the status quo (no misoprostol distribution), we developed a decision model that tracked the delivery pathways, outcomes and cost of a pregnant woman from the prenatal period to onset of labor, delivery without complications or delivery with PPH, and successful treatment or death. Model parameters were derived from the Uganda Demographic and Health Survey and the published literature, as well as expert opinion. We computed expected probabilities of PPH and death due to PPH, Disability Adjusted Life Years (DALYs) and costs. In the incremental analysis, we calculated changes in expected probabilities of PPH and death due to PPH, Disability Adjusted Life Years (DALYs) and changes in costs. We conducted univariate and probabilistic sensitivity analyses to examine robustness of our results. Results: In the base case analysis, the expected probabilities of PPH and death due to PPH were lower with prenatal misoprostol distribution (14.0% versus 16.3% and 1.4% versus 1.7% respectively). Mean DALYs were lower with prenatal misoprostol distribution (0.408 versus 0.511). Mean costs were lower with prenatal misoprostol distribution both from the governmental ($17.42 versus $18.27) and societal ($30.02 versus $31.55) perspectives. In the incremental analysis, prenatal misoprostol distribution was a dominant strategy i.e. it was both less costly and more effective. This result was robust to univariate and probabilistic sensitivity analysis. ConClusions: Prenatal distribution of misoprostol is potentially cost-effective in Uganda. It would potentially save lives and money and should be considered for national-level scale up for prevention of PPH.
PIH39

Cost-effeCtIVeness AnAlysIs of floseAl (HAeMostAtIC MAtrIx) As A HAeMostAtIC AGent In oBstetrIC HAeMorrHAGe In MexICo
PIH41
Cost-effeCtIVeness of QuAdrIVAlent Versus trIVAlent InfluenzA VACCInes for CHIldren
Yang M. C. , Tan C. H. National Taiwan University, Taipei, Taiwan objeCtives: Influenza could cause serious consequences, especially on children. The WHO recommended that influenza vaccination of children is the most effective means. Trivalent influenza vaccine (TIV), which contains two lineages of influenza A virus and one lineage of influenza B virus, is now use as a first-line strategy to prevent influenza in Taiwan. However, when the influenza B-lineage included in the TIV mismatched with circulating strains, the protection of TIV would be reduced. Quadrivalent influenza vaccine (QIV) which includes both influenza B viruses of the two circulating lineages is thus proposed as an alternative. The aim of the study was
